Clinical Trial Details
— Status: Withdrawn
Administrative data
NCT number |
NCT04349332 |
Other study ID # |
IRB20-0594 |
Secondary ID |
|
Status |
Withdrawn |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
August 13, 2020 |
Est. completion date |
January 9, 2024 |
Study information
Verified date |
April 2024 |
Source |
University of Chicago |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The objective of the study is to evaluate the efficacy of helmet NIV in reducing the duration
of invasive mechanical ventilation in order to minimize ventilator needs during the COVID-19
pandemic.
Description:
Single center randomized clinical trial investigating the efficacy of helmet NIV used for
early liberation from mechanical ventilation in patients with acute hypoxemic respiratory
failure.
Intervention: Helmet group Patients randomized to the intervention group will be extubated to
helmet NIV without a spontaneous breathing trial. The helmet will be connected to oxygen and
room air flow meter to deliver a minimum of 60L of fresh gas flow and a PEEP valve. The PEEP
will be increased using a PEEP valve in increments of 2-3 cmH20 to improve peripheral oxygen
saturation of at least 90% at an inspired oxygen requirement (FiO2) of ≤ 60%.14 After
application of the helmet, arterial blood gas sampling will be utilized to follow
gas-exchange; this is a part of usual care for the management of patients with acute
hypoxemic respiratory failure. Noninvasive support will be reduced progressively in
accordance to clinical improvement and will be discontinued if patient maintains respiratory
rate <30breaths/min and PaO2 >75mm Hg with FiO2 0.5 without ventilatory support. If
endotracheal intubation is required, the helmet will be removed and the patient will be
intubated without delay.
Control: Usual Care Patient randomized to the control group will continue invasive mechanical
ventilation until the following weaning criteria are met:15 Resolution or improvement of the
condition leading to intubation Hemodynamic stability, defined as systolic blood pressure
between 90 and 160 mm Hg and heart rate less than 140/min without vasopressors or with low
doses of vasopressors Glasgow Coma Scale score of 13 or greater Respiratory stability (oxygen
saturation >90% with fraction of inspired oxygen [Fio2] ≤0.4, respiratory rate <35/min,
Noncopious secretions (<3 aspirations in the last 8 hours).
Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30
minutes on pressure support mode. Criteria for failure to tolerate the SBT were agitation,
anxiety, low level of consciousness (Glasgow Coma Scale score <13), respiratory rate higher
than 35/min and/or use of accessory muscles, oxygen saturation by pulse oximetry less than
90% with Fio2 higher than 0.5, heart rate higher than 140/min or greater than a 20% increase
from baseline, systolic blood pressure lower than 90 mm Hg, or development of arrhythmia. If
the spontaneous breathing trial is successful, then the patient will be extubated.
Subjects will be followed for long term followup at 90 day and 1year mortality